Several uricosuric drugs are now available for the long-term management of gout, the principal being aspirin, probenecid (Benemid), and sulphinpyrazone (Anturan). Recently two further drugs, Zoxazolamine (Flexin) and p-carboxybenzenesulpha-diethylamide (Urelim), have been introduced. Reed, Feichtmeier, and Willett (1958) commented on the uricosuric properties of Zoxazolamine, and drew attention to the numerous, albeit rarely serious, side-effects. To be effective in the treatment of gout, aspirin must be administered in large doses which may not be tolerated or may provoke toxic reactions. Probenecid is known to cause severe gastritis and rashes in some patients, and may occasionally cause hypersensitivity reactions. Sulphinpyrazone has been shown to carry the same risk of peptic ulceration as phenylbutazone in the rat (Domenjoz, 1960) , and it is not unlikely that some of the other side-effects encountered with phenylbutazone may also occur with sulphinpyrazone, e.g. rashes and occasional blood dyscrasias.
The only published information concerning Urelim in the treatment of gout is a mention by Kersley, Cook, and Tovey (1958) of a comparison of this drug, then known as "Longacid", with sulphinpyrazone. They found that a dosage of 1 to 2 g. daily of Urelim resulted in an increased output of uric acid, but in only three out of eleven patients tested was the uricosuric effect equal to that obtained from 400 mg. sulphinpyrazone daily. Four patients reported drowsiness while taking Urelim, but no other side-effects were noted.
The present report is concerned with an evaluation of Urelim therapy in six patients studied in detail. Five of them suffered from primary gout and one had gout secondary to polycythaemia vera. Information was sought concerning the value of Urelim as a uricosuric agent, its dosage and optimum method of administration, effect on the serum uric acid level and the course of the illness, and any possible toxic or undesirable side-effects. The effect of aspirin given in combination with Urelim was also investigated. Only one patient was admitted to hospital during the period of investigation.
All patients were allowed a normal diet with adequate fluids, excluding only foods with a high purine content. All urine passed during the period of observation was collected in 24-hr samples, and the volume, uric acid, and creatinine contents were measured. The determination of volume and creatinine served as a check on the efficiency of collection. Serum uric acid was determined by a modification of Benedict's method, and blood urea and creatinine levels were also estimated at frequent intervals. Haemoglobin and white blood cell counts were also determined before and during the treatment periods. Special care was taken to ensure that no drugs with uricosuric effect, other than those prescribed, were administered during these studies. May, 1960 , and after treatment with colchicine and probenecid he was given delta-butazolidin. This was discontinued on July 20, 1960, and after a control period of 5 days without any treatment, the patient started Urelim therapy. His gout remained quiescent throughout the period of investigation. The findings are summarized in Table II. Case 3, a retired shopkeeper aged 66 years, had suffered from polycythaemia vera for 12 years and had developed gout in several joints in his hands and feet since 1956. He had been given colchicine tablets and probenecid intermittently since then and had taken probenecid 2 g. daily for 3 months before having a short trial of Urelim therapy. This patient also suffered from the mild residual effects of a left cerebral thrombosis, and observations were limited as he was treated at home. The findings are summarized in Table III . 
Discussion
In three patients (Cases 1, 2, and 5) it was possible to obtain a direct measurement of the uricosuric effect of Urelim after a control period.
In Case 1, the uric acid output was raised by 28 per cent. during treatment with Urelim 0 5 g. daily and there was no greater output when the dosage was increased to 1 g. daily (Table 1) .
Case 2 showed an increase of 33 per cent. uric acid output on 1 g. Urelim daily and 51 per cent. when the dosage was raised to 2 g. (Table II) .
Case 5 showed an increased uric acid output of 46 per cent. when given 1 g. Urelim daily (Table V) .
These results support the claim that Urelim is a potent uricosuric agent, and indicate that 1 g. daily will increase the uric acid output by as much as 28 to 46 per cent. Increasing the Urelim dosage (from 0 5 to 1 g. daily) did not result in an increase in uric acid excretion in Case 1; this was probably due to the fact that this patient took the daily dosage of two tablets both together. This induced slight and transient drowsiness which later ceased when he took the drug in divided doses. It seems advisable that the Urelim dosage should be distributed throughout the day, in keeping with the recommended method of administration of other uricosuric agents, e.g. probenecid (Br0chner-Mortensen, 1958) and sulphinpyrazone (Kersley and others, 1958) .
Urelim was well tolerated by all the patients in this series and during the short periods of treatment, ranging from 9 to 72 days, no serious side-effects occurred. As already mentioned, one patient (Case 1) noted slight and transient drowsiness about 4 hours after taking 1 g. Urelim, but he has sub- 60 days with no upset other than the mild urticarial rash which was not necessarily due to Urelim. Case 6 had previously experienced severe hypersensitivity reactions, with malaise, rash, and vomiting, on the several occasions on which she had attempted to take probenecid, and large doses of aspirin were not tolerated, but she was able to take 1 g. Urelim daily without upset. No significant alterations in white blood cell counts were noted during the periods of observation in these six patients.
The short-term effects of a uricosuric agent are not so evident in changes in the serum uric acid level as in the urinary uric acid output, and with small doses of aspirin the serum uric acid level may rise even though the urinary uric acid excretion rises (Br0chner-Mortensen, 1958) . There were four patients in our series in whom the effect of Urelim on the serum uric acid level was observed. In Case 1 the serum uric acid level rose from 9 5 to 9-6 mg./l00 ml. on 0 5 g. Urelim daily, and from 9 6 to 10-7 mg./I00 ml. on 1 g. Urelim daily, even though the urinary uric acid output had increased (Table I) . Case 2 showed a fall in the serum uric acid level from 8 4 to 7 1 mg./l00 ml. on 1 g. Urelim daily, and from 7-1 to 5-4 mg./l00 ml. on 2 g. Urelim daily, this being associated with successive increases in urinary uric acid output (Table II) . Case 5 also showed a steady fall from 6 7 to 4 0 mg./l00 ml. on 1 g. Urelim (Table V) and this was correlated with increased urinary uric acid output. Case 6 received only a small dosage of 0 5 g. Urelim daily for 1 week increasing to 1 g. daily for 10 days, and the serum uric acid level fell from 9-8 to 8-8 mg./l00 ml.
From present data it can be said that Urelim is an effective uricosuric drug. The question of the potency of Urelim milligram for milligram in comparison with probenecid and sulphinpyrazone is of little moment. The important points concerning a drug are whether it is effective and whether it can be taken without undesirable side-effects, and short-term studies suggest that Urelim meets these requirements.
In view of the known inhibiting effect of salicylate upon the uricosuric actions of probenecid (Br0chner- Mortensen, 1958 ) and sulphinpyrazone (Ogryzlo and Harrison, 1957) , and in view of the widespread use of analgesics containing aspirin, it seemed advisable to investigate the influence of aspirin upon the uricosuric effect of Urelim. Aspirin in a dosage of 4 8 g. (72 gr.) daily was administered to Cases 2 and 5. In both patients the serum uric acid levels rose quickly and appreciably, but there was little effect on the urinary uric acid output. These findings suggest that patients receiving Urelim should be advised to avoid analgesics containing aspirin.
We have studied the effect of some of these drugs in combination and in sequence. There was a dramatic fall in urinary uric acid output when a patient was transferred immediately from 2 g. Urelim to 300 mg. sulphinpyrazone daily (Table II) . The combinations of Urelim and probenecid (Table I) , and of Urelim and sulphinpyrazone (Table IV) 
